Minerva Neurosciences, Inc.

NASDAQ:NERV

Biotechnology

Healthcare
$2.16 -6.49%

-$0.30 today

Market cap
$107.64M
Beta
-0.11
P/E (TTM)
-0.2
EPS (TTM)
-$8.46
52W Low $1.76High $12.46

Volume 0.15M

Average 0.21M

Returns on capital

Minerva Neurosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

208.5%

avg -51.9%

ROIC

-15.8%

avg -40.1%

ROA

-299.5%

avg -61.0%

Analysis

ROE is currently the strongest return metric at 208.5% versus its period average of -51.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Remy Luthringer

Executive Chairman, CEO & Member of Scientific Advisory BoardUSD 1.16M651.69M3.63%

Michael Davidson

Member of Scientific Advisory Board & Chief Medical OfficerUSD 657.47K7685.00K0.18%

Frederick W. Ahlholm

Senior Vice President, Chief Financial Officer & SecretaryUSD 649.21K60680.00K1.46%

Joseph Reilly

Senior Vice President & Chief Operating OfficerUSD 461K51——

Anthony Aliquo

Chief Accounting Officer & Principal Accounting Officer—391.68K<0.01%

James O'Connor

Chief Business Officer & General Counsel—52——

William Boni

Vice President of Investor Relations & Corporation Communications—74——

Compensation is shown in the reported currency; data updated Nov 18, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Minerva Neurosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NERV's management, answered from reported figures.

Who manages NERV?

Minerva Neurosciences, Inc. (NERV) lists 7 active executives. The top listed executive is Remy Luthringer, Executive Chairman, CEO & Member of Scientific Advisory Board.

Are NERV insiders buying or selling?

Recent insider activity shows net buying of $64.00M.